ACE2 News and Research

RSS

Does SARS-CoV-2 alter the expression of molecules involved in the homeostasis of blood pressure?

A recent study finds that COVID-19 alters the expression of several molecules involved in the homeostasis of blood pressure.

22 Jun 2021

Research identifies SARS-CoV-2 cavities as potential drug targets

New research found the SARS-CoV-2 spike glycoprotein has druggable cavities with the best target being compatible with more than 1 billion compounds.

21 Jun 2021

Can a prior rhinovirus infection protect against COVID-19?

Researchers at the Yale School of Medicine found that rhinovirus accelerates interferon-stimulated genes.

21 Jun 2021

Study shows that COVID-19 was present in five U.S. states in December 2019, even before the first reported case in China

In a recent study, a group of researchers aimed to identify exactly how early SARS-CoV-2 was circulating throughout the United States.

21 Jun 2021

Common blood pressure drug not effective in reducing hospitalization for mildly-ill COVID-19 outpatients

University of Minnesota Medical School researchers determined that the common blood pressure medication, losartan, is not effective in reducing hospitalization for mildly-ill COVID-19 outpatients.

18 Jun 2021

RIG-1 agonist shows potent antiviral efficacy against SARS-CoV-2 infection

A team of scientists from the United States has recently revealed the antiviral efficacy of stem-loop RNA 14, a RIG-1 agonist, in controlling severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in mice. The compound reduces the risk of severe coronavirus disease 2019 (COVID-19) by inhibiting viral replication in the lower respiratory tract. The study is currently available on the bioRxiv* preprint server.

18 Jun 2021

Nanodecoys made from human lung spheroid cells can neutralize SARS-CoV-2

Nanodecoys made from human lung spheroid cells (LSCs) can bind to and neutralize SARS-CoV-2, promoting viral clearance and reducing lung injury in a macaque model of COVID-19.

18 Jun 2021

Which vitamins and minerals help with COVID?

A study published in the journal Inflammopharmacology reviewed recent data related to the role of vitamins and minerals in treating COVID-19 patients. The primary goal of the review is to highlight the possible therapeutic role of vitamins A, B, C, D, E and K, and micronutrients as immunity boosters in COVID-19 patients.

18 Jun 2021

Novel ferritin nanoparticle vaccine candidate effective against SARS-CoV-2 variants in preclinical trials

A team of scientists from the United States has recently evaluated the efficacy of a ferritin nanoparticle-formulated, SARS-CoV-2 spike-based vaccine against newly emerged Variants of Concern (VOCs).

17 Jun 2021

How the common cold can provide protection against COVID-19

In a recent study, researchers found that prior infection with the rhinovirus can provide a more effective immune response against SARS-CoV-2 infection.

17 Jun 2021

Antibody combination REGEN-COV prevents symptomatic disease following SARS-CoV-2 infection

Researchers in the United States have demonstrated the effectiveness of early treatment with REGEN-COV™ at preventing symptomatic disease among people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

17 Jun 2021

Long-term exposure to poor air quality increases COVID-19 risk, research finds

Even as governments across the United States consider lifting mask mandates and relaxing preventative measures as vaccination numbers creep up, new research from a UCLA-led team has found that such basic techniques significantly reduce the risk of getting COVID-19.

16 Jun 2021

Study observes increased breadth of SARS-CoV-2 antibody neutralization acquired over one year

A new paper in the journal Nature offers a reassuring answer, showing that convalescent COVID-19 patients, some of whom had received vaccination as well, retain antiviral antibodies and neutralizing activity, as well as memory B cells, for up to 6-12 months from infection.

16 Jun 2021

Cissampelos pareira (velvetleaf) exhibits anti-SARS-CoV-2 potential

Cissampelos pareira (Cipa), also known as velvetleaf, is a widely used hormone modulator used to treat reproductive disorders and fever. Research has shown that it can inhibit three serotypes of Dengue virus (DENV) and affect various hormones.

16 Jun 2021

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

The authors of the review have grouped the virus proteins into three categories, (a) host-entry, (b) self-acting, and (c) host-interacting. Additionally, individual SARS-CoV-2 proteins are evaluated to be either directly targeted by drugs or block virus-host interactions.

16 Jun 2021

SARS-CoV-2 oral vaccine booster shows promise in animal tests

In a recent study published on the pre-print bioRxiv* server, a group of Israeli researchers discusses their progress towards developing an oral multi-antigen SARS-CoV-2 vaccine.

15 Jun 2021

RBD and NTD antibody cocktail could prevent the emergence of SARS-CoV-2 escape mutants

A new bioRxiv* preprint demonstrates how a combination of antibodies to two different regions on the viral spike could enhance neutralization efficiency as well as prevent the emergence of resistant variants.

15 Jun 2021

Fusogenicity and resistance of SARS-CoV-2 B.1.1.7 and B.1.351 compared to D614G

A new study, released as a preprint on the bioRxiv* server, describes the biological effects induced by mutations in two circulating VOCs. These are the alpha and beta strains, also called B.1.1.7 and B.1.351, respectively.

15 Jun 2021

Potent antibodies against SARS-CoV-2 can be produced without T follicular helper cells, suggests study

It has been uncertain whether antibodies produced via this non-canonical pathway are protective against SARS-CoV-2. In a new study, recently released as a preprint on the bioRxiv*server, the neutralization potency of these antibodies is compared with those traditionally produced in germinal center-based antiviral responses.

15 Jun 2021

Alkaloids show potential as treatments for COVID-19

To further study these organic compounds, researchers from Kermanshah University of Medical Sciences, Iran, and Universidad de Santiago de Chile, Chile, reviewed the role of alkaloids as a potential antiviral, specifically against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They presented the chemistry, plant sources, and antiviral effects of alkaloids and their anti-SARS-CoV-2 effect.

15 Jun 2021

ACE2 News and Research

Does SARS-CoV-2 alter the expression of molecules involved in the homeostasis of blood pressure?

Research identifies SARS-CoV-2 cavities as potential drug targets

Can a prior rhinovirus infection protect against COVID-19?

Study shows that COVID-19 was present in five U.S. states in December 2019, even before the first reported case in China

Common blood pressure drug not effective in reducing hospitalization for mildly-ill COVID-19 outpatients

RIG-1 agonist shows potent antiviral efficacy against SARS-CoV-2 infection

Nanodecoys made from human lung spheroid cells can neutralize SARS-CoV-2

Which vitamins and minerals help with COVID?

Novel ferritin nanoparticle vaccine candidate effective against SARS-CoV-2 variants in preclinical trials

How the common cold can provide protection against COVID-19

Antibody combination REGEN-COV prevents symptomatic disease following SARS-CoV-2 infection

Long-term exposure to poor air quality increases COVID-19 risk, research finds

Study observes increased breadth of SARS-CoV-2 antibody neutralization acquired over one year

Cissampelos pareira (velvetleaf) exhibits anti-SARS-CoV-2 potential

A study on SARS-CoV-2 proteins for the development of COVID-19 drugs

SARS-CoV-2 oral vaccine booster shows promise in animal tests

RBD and NTD antibody cocktail could prevent the emergence of SARS-CoV-2 escape mutants

Fusogenicity and resistance of SARS-CoV-2 B.1.1.7 and B.1.351 compared to D614G

Potent antibodies against SARS-CoV-2 can be produced without T follicular helper cells, suggests study

Alkaloids show potential as treatments for COVID-19

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News